- Home
- EDUC vs SYBX Comparison
EDUC vs SYBX Comparison
Compare EDUC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- SYBX
- Stock Information
- Founded
- EDUC 1965
- SYBX N/A
- Country
- EDUC United States
- SYBX United States
- Employees
- EDUC N/A
- SYBX N/A
- Industry
- EDUC Consumer Specialties
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- SYBX Health Care
- Exchange
- EDUC Nasdaq
- SYBX Nasdaq
- Market Cap
- EDUC 14.6M
- SYBX 17.0M
- IPO Year
- EDUC N/A
- SYBX N/A
- Fundamental
- Price
- EDUC $1.67
- SYBX $1.44
- Analyst Decision
- EDUC
- SYBX Hold
- Analyst Count
- EDUC 0
- SYBX 3
- Target Price
- EDUC N/A
- SYBX $1.00
- AVG Volume (30 Days)
- EDUC 15.7K
- SYBX 35.0K
- Earning Date
- EDUC 01-13-2025
- SYBX 11-12-2024
- Dividend Yield
- EDUC N/A
- SYBX N/A
- EPS Growth
- EDUC N/A
- SYBX N/A
- EPS
- EDUC N/A
- SYBX N/A
- Revenue
- EDUC $36,523,200.00
- SYBX $2,777,000.00
- Revenue This Year
- EDUC N/A
- SYBX N/A
- Revenue Next Year
- EDUC N/A
- SYBX N/A
- P/E Ratio
- EDUC N/A
- SYBX N/A
- Revenue Growth
- EDUC N/A
- SYBX 292.23
- 52 Week Low
- EDUC $1.36
- SYBX $1.22
- 52 Week High
- EDUC $2.95
- SYBX $3.86
- Technical
- Relative Strength Index (RSI)
- EDUC 43.24
- SYBX 51.37
- Support Level
- EDUC $1.58
- SYBX $1.36
- Resistance Level
- EDUC $1.78
- SYBX $1.51
- Average True Range (ATR)
- EDUC 0.13
- SYBX 0.09
- MACD
- EDUC 0.01
- SYBX 0.00
- Stochastic Oscillator
- EDUC 38.10
- SYBX 34.78
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.